Intracellular signaling pathways involved in inhibition of PAI-1 expression by CNP in endothelial cells

Area of Science:

• Vascular Biology
• Molecular Signaling
• Cardiovascular Research

Background:

• Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of fibrinolysis, implicated in inflammatory and cardiovascular diseases.
• Tumor necrosis factor-alpha (TNFα) stimulates PAI-1 expression, contributing to vascular pathology.
• Natriuretic peptides, particularly C-type natriuretic peptide (CNP), have emerged as potential modulators of vascular inflammation.

Purpose of the Study:

• To elucidate the molecular mechanisms by which CNP modulates PAI-1 expression in human endothelial cells.
• To investigate the role of specific signaling pathways, including MAP kinase, PI3K/AKT, and cGMP, in CNP's inhibitory effects.

Main Methods:

• Human endothelial cells were treated with CNP and/or TNFα.
• Levels of cyclic guanosine monophosphate (cGMP) were measured.
• The phosphorylation status of ERK1/2 and JNK kinases was assessed.
• The impact of CNP and pathway inhibitors (PD098059, LY294002) on TNFα-induced PAI-1 expression was evaluated.

Main Results:

• CNP significantly increased intracellular cGMP levels in endothelial cells.
• 8-Br-cGMP, a cGMP analogue, inhibited TNFα-induced PAI-1 expression.
• CNP and inhibitors of ERK1/2 (PD098059) and PI3K (LY294002) attenuated TNFα-induced PAI-1 expression.
• CNP specifically inhibited TNFα-induced ERK1/2 phosphorylation without affecting JNK phosphorylation.

Conclusions:

• CNP exerts its inhibitory effect on TNFα-induced PAI-1 expression via modulation of the PI3K/AKT and MEK/ERK signaling pathways.
• CNP may act as a natural defense mechanism for the vascular wall against cytokine-induced PAI-1 release.
• These findings highlight CNP's therapeutic potential in managing vascular inflammatory conditions.